Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma

European Journal of Cancer

Volumn 48, Issue 7, 2012, Pages 1023-1030

  Seidel, Christoph ^a   Busch, Jonas ^b   Weikert, Steffen ^b   Steffens, Sandra ^a   Fenner, Martin ^a   Ganser, Arnold ^a   Grünwald, Viktor ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Axitinib; Prognostic; Progression free survival; Renal cell carcinoma; Sorafenib; Sunitinib; Tyrosine kinase inhibitor; VEGF targeted therapy

Indexed keywords

AXITINIB; EVEROLIMUS; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CONTROLLED STUDY; DIPLOPIA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; LEG ULCER; LOG RANK TEST; LUNG ALVEOLITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; PROTEINURIA; RETROSPECTIVE STUDY; SCORING SYSTEM; SMALL INTESTINE PERFORATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGNOSIS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859488442     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.02.048     Document Type: Article

References (28)

1. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
2. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
3. B.J. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
4. B.J. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised double blind phase III trial Lancet 370 2007 2103 2111
5. R.J. Motzer, B.J. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
6. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 9807 2011 1931 1939 [Epub 2011 Nov 4]
7. R.J. Motzer, J. Bacik, and B.A. Murphy Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 2002 289 296
8. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
9. J. Busch, C. Seidel, and S. Weikert Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma BMC Cancer 14 11 2011 295
10. D.Y.C. Heng, W. Xie, and G.A. Bjarnason Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy Cancer 2010 [Epub ahead of print]
11. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
12. M.Y. Al-Marrawi, B.I. Rini, and G.A. Harshman The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts.) J Clin Oncol 29 2011 [abstr. 4555]
13. R.J. Motzer, T.E. Hutson, and M.R. Olsen Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continupus dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial J Clin Oncol 29 2011 [suppl. 7, abstr. LBA308]
14. C. Porta, G. Procopio, and G. Carteni Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases BJU Int 108 2011 E250 E257
15. D.Y. Heng, M.J. MacKenzie, and U.N. Vaishampayan Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy J Clin Oncol 29 2011 [suppl. 7, abstr. 305]
16. Y. Liu, H. Tran, and A. Lin Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC) J Clin Oncol 29 2011 [abstr. 4553]
17. T.K. Choueiri, M.M. Regan, and J.E. Rosenberg Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy BJU Int 106 2010 772 778
18. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
19. B. Rini, E. Jaeger, and V. Weinberg Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status BJU Int 98 2006 756 762
20. B.I. Rini, M.D. Michaelson, and J.E. Rosenberg Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 2008 3743 3748
21. V. Gruenwald, G. Beutel, and S. Schuch-Jantsch Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib BMC Cancer 10 2010 695
22. L. Vroling, A.A.M. van der Veldt, and R.R. de Haas Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib Angiogenesis 12 2009 69 79
23. S.E. Deprimo, C.L. Bello, and J. Smeraglia Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins J Transl Med 1 5 2007 32
24. T. O'Reilly, and P.M. McSheehy Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals Transl Oncol 3 2010 65 79
25. L. Lee, S. Sharma, and B. Morgan Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases Cancer Chemother Pharmacol 57 2006 761 771
26. A. Norden-Zfoni, J. Desai, and J. Manola Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor Clin Cancer Res 13 2007 2643 2650
27. L.J. Nissen, R. Cao, and E. Hedlund Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis J Clin Invest 117 2007 2766 2777
28. Escudier B, Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS trial). ECCO16-ESMO36 congress 2011 [abstr. 7103].